Antithrombin III is associated with acute liver failure in patients with end-stage heart failure undergoing mechanical circulatory support

Abstract Objective There are few data on the role of liver dysfunction in patients with end-stage heart failure supported by mechanical circulatory support. The aim of our study was to investigate predictors for acute liver failure in patients with end-stage heart failure undergoing mechanical circu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of thoracic and cardiovascular surgery 2017-06, Vol.153 (6), p.1374-1382
Hauptverfasser: Hoefer, Judith, MD, Ulmer, Hanno, PhD, Kilo, Juliane, MD, Margreiter, Raimund, MD, Grimm, Michael, MD, Mair, Peter, MD, Ruttmann, Elfriede, MD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1382
container_issue 6
container_start_page 1374
container_title The Journal of thoracic and cardiovascular surgery
container_volume 153
creator Hoefer, Judith, MD
Ulmer, Hanno, PhD
Kilo, Juliane, MD
Margreiter, Raimund, MD
Grimm, Michael, MD
Mair, Peter, MD
Ruttmann, Elfriede, MD
description Abstract Objective There are few data on the role of liver dysfunction in patients with end-stage heart failure supported by mechanical circulatory support. The aim of our study was to investigate predictors for acute liver failure in patients with end-stage heart failure undergoing mechanical circulatory support. Methods A consecutive 164 patients with heart failure with New York Heart Association class IV undergoing mechanical circulatory support were investigated for acute liver failure using the King's College criteria. Clinical characteristics of heart failure together with hemodynamic and laboratory values were analyzed by logistic regression. Results A total of 45 patients (27.4%) with heart failure developed subsequent acute liver failure with a hospital mortality of 88.9%. Duration of heart failure, cause, cardiopulmonary resuscitation, use of vasopressors, central venous pressure, pulmonary capillary wedge pressure, pulmonary pulsatility index, cardiac index, and transaminases were not significantly associated with acute liver failure. Repeated decompensation, atrial fibrillation ( P  
doi_str_mv 10.1016/j.jtcvs.2017.01.053
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1876493996</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022522317302039</els_id><sourcerecordid>1876493996</sourcerecordid><originalsourceid>FETCH-LOGICAL-c459t-372c9b8afe10892c7440744f8d62e6d2a4d8696b8cba7302a3c75754fae0f74c3</originalsourceid><addsrcrecordid>eNqFks9u1DAQxi0EotvCEyAhH7kkjO0kjg8gVRWUlSpxACRuluNMdh3yZ7GdRfsKPDVOt_TAhYM1B_--Gc33DSGvGOQMWPW2z_tojyHnwGQOLIdSPCEbBkpmVV1-f0o2AJxnJefiglyG0AOABKaekwtec1mUFWzI7-spurj389i4iW63W-oCNSHM1pmILf2VPqmxS0Q6uCN62hk3LB5pog8mOpxiOEM4tVmIZod0j8bHR3CZWvS72U07OqLdm8lZM1DrvF0GE2d_omE5HGYfX5BnnRkCvnyoV-Tbxw9fbz5ld59vtzfXd5ktShUzIblVTW06ZFArbmVRQHpd3VYcq5aboq0rVTW1bYwUwI2wspRl0RmEThZWXJE3574HP_9cMEQ9umBxGMyE8xI0q2VVKKFUlVBxRq2fQ_DY6YN3o_EnzUCvIehe34eg1xA0MJ1CSKrXDwOWZsT2UfPX9QS8OwOY1jw69DrY5KTF1nm0Ubez-8-A9__o7eDuff2BJwz9vPgpOaiZDlyD_rLewXoGbPUDhBJ_ADEbsVE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1876493996</pqid></control><display><type>article</type><title>Antithrombin III is associated with acute liver failure in patients with end-stage heart failure undergoing mechanical circulatory support</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Hoefer, Judith, MD ; Ulmer, Hanno, PhD ; Kilo, Juliane, MD ; Margreiter, Raimund, MD ; Grimm, Michael, MD ; Mair, Peter, MD ; Ruttmann, Elfriede, MD</creator><creatorcontrib>Hoefer, Judith, MD ; Ulmer, Hanno, PhD ; Kilo, Juliane, MD ; Margreiter, Raimund, MD ; Grimm, Michael, MD ; Mair, Peter, MD ; Ruttmann, Elfriede, MD ; Innsbruck Liver-in-Heart-Failure Program</creatorcontrib><description>Abstract Objective There are few data on the role of liver dysfunction in patients with end-stage heart failure supported by mechanical circulatory support. The aim of our study was to investigate predictors for acute liver failure in patients with end-stage heart failure undergoing mechanical circulatory support. Methods A consecutive 164 patients with heart failure with New York Heart Association class IV undergoing mechanical circulatory support were investigated for acute liver failure using the King's College criteria. Clinical characteristics of heart failure together with hemodynamic and laboratory values were analyzed by logistic regression. Results A total of 45 patients (27.4%) with heart failure developed subsequent acute liver failure with a hospital mortality of 88.9%. Duration of heart failure, cause, cardiopulmonary resuscitation, use of vasopressors, central venous pressure, pulmonary capillary wedge pressure, pulmonary pulsatility index, cardiac index, and transaminases were not significantly associated with acute liver failure. Repeated decompensation, atrial fibrillation ( P  &lt; .001) and the use of inotropes ( P  = .007), mean arterial ( P  = .005) and pulmonary pressures ( P  = .042), cholinesterase, international normalized ratio, bilirubin, lactate, and pH ( P  &lt; .001) were predictive of acute liver failure in univariate analysis only. In multivariable analysis, decreased antithrombin III was the strongest single measurement indicating acute liver failure (relative risk per %, 0.84; 95% confidence interval, 0.77-0.93; P  = .001) and remained an independent predictor when adjustment for the Model for End-Stage Liver Disease score was performed (relative risk per %, 0.89; 95% confidence interval, 0.80-0.99; P  = .031). Antithrombin III less than 59.5% was identified as a cutoff value to predict acute liver failure with a corresponding sensitivity of 81% and specificity of 87%. Conclusions In addition to the Model for End-Stage Liver Disease score, decreased antithrombin III activity tends to be superior in predicting acute liver failure compared with traditionally thought predictors. Antithrombin III measurement may help to identify patients more precisely who are developing acute liver failure during mechanical circulatory support.</description><identifier>ISSN: 0022-5223</identifier><identifier>EISSN: 1097-685X</identifier><identifier>DOI: 10.1016/j.jtcvs.2017.01.053</identifier><identifier>PMID: 28274560</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>acute liver failure ; Adult ; Aged ; Antithrombin III - metabolism ; Biomarkers - blood ; cardiogenic shock ; Cardiothoracic Surgery ; extracorporeal membrane oxygenation ; Extracorporeal Membrane Oxygenation - adverse effects ; Extracorporeal Membrane Oxygenation - mortality ; Female ; Heart Failure - blood ; Heart Failure - mortality ; Heart Failure - physiopathology ; Heart Failure - therapy ; Hemodynamics ; Hospital Mortality ; Humans ; Liver Failure, Acute - blood ; Liver Failure, Acute - diagnosis ; Liver Failure, Acute - mortality ; Liver Failure, Acute - physiopathology ; Liver Function Tests ; Male ; mechanical circulatory support ; Middle Aged ; Predictive Value of Tests ; Retrospective Studies ; Risk Factors ; Shock, Cardiogenic - blood ; Shock, Cardiogenic - mortality ; Shock, Cardiogenic - physiopathology ; Shock, Cardiogenic - therapy ; Time Factors ; Treatment Outcome</subject><ispartof>The Journal of thoracic and cardiovascular surgery, 2017-06, Vol.153 (6), p.1374-1382</ispartof><rights>The American Association for Thoracic Surgery</rights><rights>2017 The American Association for Thoracic Surgery</rights><rights>Copyright © 2017 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c459t-372c9b8afe10892c7440744f8d62e6d2a4d8696b8cba7302a3c75754fae0f74c3</citedby><cites>FETCH-LOGICAL-c459t-372c9b8afe10892c7440744f8d62e6d2a4d8696b8cba7302a3c75754fae0f74c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0022522317302039$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28274560$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hoefer, Judith, MD</creatorcontrib><creatorcontrib>Ulmer, Hanno, PhD</creatorcontrib><creatorcontrib>Kilo, Juliane, MD</creatorcontrib><creatorcontrib>Margreiter, Raimund, MD</creatorcontrib><creatorcontrib>Grimm, Michael, MD</creatorcontrib><creatorcontrib>Mair, Peter, MD</creatorcontrib><creatorcontrib>Ruttmann, Elfriede, MD</creatorcontrib><creatorcontrib>Innsbruck Liver-in-Heart-Failure Program</creatorcontrib><title>Antithrombin III is associated with acute liver failure in patients with end-stage heart failure undergoing mechanical circulatory support</title><title>The Journal of thoracic and cardiovascular surgery</title><addtitle>J Thorac Cardiovasc Surg</addtitle><description>Abstract Objective There are few data on the role of liver dysfunction in patients with end-stage heart failure supported by mechanical circulatory support. The aim of our study was to investigate predictors for acute liver failure in patients with end-stage heart failure undergoing mechanical circulatory support. Methods A consecutive 164 patients with heart failure with New York Heart Association class IV undergoing mechanical circulatory support were investigated for acute liver failure using the King's College criteria. Clinical characteristics of heart failure together with hemodynamic and laboratory values were analyzed by logistic regression. Results A total of 45 patients (27.4%) with heart failure developed subsequent acute liver failure with a hospital mortality of 88.9%. Duration of heart failure, cause, cardiopulmonary resuscitation, use of vasopressors, central venous pressure, pulmonary capillary wedge pressure, pulmonary pulsatility index, cardiac index, and transaminases were not significantly associated with acute liver failure. Repeated decompensation, atrial fibrillation ( P  &lt; .001) and the use of inotropes ( P  = .007), mean arterial ( P  = .005) and pulmonary pressures ( P  = .042), cholinesterase, international normalized ratio, bilirubin, lactate, and pH ( P  &lt; .001) were predictive of acute liver failure in univariate analysis only. In multivariable analysis, decreased antithrombin III was the strongest single measurement indicating acute liver failure (relative risk per %, 0.84; 95% confidence interval, 0.77-0.93; P  = .001) and remained an independent predictor when adjustment for the Model for End-Stage Liver Disease score was performed (relative risk per %, 0.89; 95% confidence interval, 0.80-0.99; P  = .031). Antithrombin III less than 59.5% was identified as a cutoff value to predict acute liver failure with a corresponding sensitivity of 81% and specificity of 87%. Conclusions In addition to the Model for End-Stage Liver Disease score, decreased antithrombin III activity tends to be superior in predicting acute liver failure compared with traditionally thought predictors. Antithrombin III measurement may help to identify patients more precisely who are developing acute liver failure during mechanical circulatory support.</description><subject>acute liver failure</subject><subject>Adult</subject><subject>Aged</subject><subject>Antithrombin III - metabolism</subject><subject>Biomarkers - blood</subject><subject>cardiogenic shock</subject><subject>Cardiothoracic Surgery</subject><subject>extracorporeal membrane oxygenation</subject><subject>Extracorporeal Membrane Oxygenation - adverse effects</subject><subject>Extracorporeal Membrane Oxygenation - mortality</subject><subject>Female</subject><subject>Heart Failure - blood</subject><subject>Heart Failure - mortality</subject><subject>Heart Failure - physiopathology</subject><subject>Heart Failure - therapy</subject><subject>Hemodynamics</subject><subject>Hospital Mortality</subject><subject>Humans</subject><subject>Liver Failure, Acute - blood</subject><subject>Liver Failure, Acute - diagnosis</subject><subject>Liver Failure, Acute - mortality</subject><subject>Liver Failure, Acute - physiopathology</subject><subject>Liver Function Tests</subject><subject>Male</subject><subject>mechanical circulatory support</subject><subject>Middle Aged</subject><subject>Predictive Value of Tests</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Shock, Cardiogenic - blood</subject><subject>Shock, Cardiogenic - mortality</subject><subject>Shock, Cardiogenic - physiopathology</subject><subject>Shock, Cardiogenic - therapy</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>0022-5223</issn><issn>1097-685X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFks9u1DAQxi0EotvCEyAhH7kkjO0kjg8gVRWUlSpxACRuluNMdh3yZ7GdRfsKPDVOt_TAhYM1B_--Gc33DSGvGOQMWPW2z_tojyHnwGQOLIdSPCEbBkpmVV1-f0o2AJxnJefiglyG0AOABKaekwtec1mUFWzI7-spurj389i4iW63W-oCNSHM1pmILf2VPqmxS0Q6uCN62hk3LB5pog8mOpxiOEM4tVmIZod0j8bHR3CZWvS72U07OqLdm8lZM1DrvF0GE2d_omE5HGYfX5BnnRkCvnyoV-Tbxw9fbz5ld59vtzfXd5ktShUzIblVTW06ZFArbmVRQHpd3VYcq5aboq0rVTW1bYwUwI2wspRl0RmEThZWXJE3574HP_9cMEQ9umBxGMyE8xI0q2VVKKFUlVBxRq2fQ_DY6YN3o_EnzUCvIehe34eg1xA0MJ1CSKrXDwOWZsT2UfPX9QS8OwOY1jw69DrY5KTF1nm0Ubez-8-A9__o7eDuff2BJwz9vPgpOaiZDlyD_rLewXoGbPUDhBJ_ADEbsVE</recordid><startdate>20170601</startdate><enddate>20170601</enddate><creator>Hoefer, Judith, MD</creator><creator>Ulmer, Hanno, PhD</creator><creator>Kilo, Juliane, MD</creator><creator>Margreiter, Raimund, MD</creator><creator>Grimm, Michael, MD</creator><creator>Mair, Peter, MD</creator><creator>Ruttmann, Elfriede, MD</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170601</creationdate><title>Antithrombin III is associated with acute liver failure in patients with end-stage heart failure undergoing mechanical circulatory support</title><author>Hoefer, Judith, MD ; Ulmer, Hanno, PhD ; Kilo, Juliane, MD ; Margreiter, Raimund, MD ; Grimm, Michael, MD ; Mair, Peter, MD ; Ruttmann, Elfriede, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c459t-372c9b8afe10892c7440744f8d62e6d2a4d8696b8cba7302a3c75754fae0f74c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>acute liver failure</topic><topic>Adult</topic><topic>Aged</topic><topic>Antithrombin III - metabolism</topic><topic>Biomarkers - blood</topic><topic>cardiogenic shock</topic><topic>Cardiothoracic Surgery</topic><topic>extracorporeal membrane oxygenation</topic><topic>Extracorporeal Membrane Oxygenation - adverse effects</topic><topic>Extracorporeal Membrane Oxygenation - mortality</topic><topic>Female</topic><topic>Heart Failure - blood</topic><topic>Heart Failure - mortality</topic><topic>Heart Failure - physiopathology</topic><topic>Heart Failure - therapy</topic><topic>Hemodynamics</topic><topic>Hospital Mortality</topic><topic>Humans</topic><topic>Liver Failure, Acute - blood</topic><topic>Liver Failure, Acute - diagnosis</topic><topic>Liver Failure, Acute - mortality</topic><topic>Liver Failure, Acute - physiopathology</topic><topic>Liver Function Tests</topic><topic>Male</topic><topic>mechanical circulatory support</topic><topic>Middle Aged</topic><topic>Predictive Value of Tests</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Shock, Cardiogenic - blood</topic><topic>Shock, Cardiogenic - mortality</topic><topic>Shock, Cardiogenic - physiopathology</topic><topic>Shock, Cardiogenic - therapy</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hoefer, Judith, MD</creatorcontrib><creatorcontrib>Ulmer, Hanno, PhD</creatorcontrib><creatorcontrib>Kilo, Juliane, MD</creatorcontrib><creatorcontrib>Margreiter, Raimund, MD</creatorcontrib><creatorcontrib>Grimm, Michael, MD</creatorcontrib><creatorcontrib>Mair, Peter, MD</creatorcontrib><creatorcontrib>Ruttmann, Elfriede, MD</creatorcontrib><creatorcontrib>Innsbruck Liver-in-Heart-Failure Program</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of thoracic and cardiovascular surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hoefer, Judith, MD</au><au>Ulmer, Hanno, PhD</au><au>Kilo, Juliane, MD</au><au>Margreiter, Raimund, MD</au><au>Grimm, Michael, MD</au><au>Mair, Peter, MD</au><au>Ruttmann, Elfriede, MD</au><aucorp>Innsbruck Liver-in-Heart-Failure Program</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antithrombin III is associated with acute liver failure in patients with end-stage heart failure undergoing mechanical circulatory support</atitle><jtitle>The Journal of thoracic and cardiovascular surgery</jtitle><addtitle>J Thorac Cardiovasc Surg</addtitle><date>2017-06-01</date><risdate>2017</risdate><volume>153</volume><issue>6</issue><spage>1374</spage><epage>1382</epage><pages>1374-1382</pages><issn>0022-5223</issn><eissn>1097-685X</eissn><abstract>Abstract Objective There are few data on the role of liver dysfunction in patients with end-stage heart failure supported by mechanical circulatory support. The aim of our study was to investigate predictors for acute liver failure in patients with end-stage heart failure undergoing mechanical circulatory support. Methods A consecutive 164 patients with heart failure with New York Heart Association class IV undergoing mechanical circulatory support were investigated for acute liver failure using the King's College criteria. Clinical characteristics of heart failure together with hemodynamic and laboratory values were analyzed by logistic regression. Results A total of 45 patients (27.4%) with heart failure developed subsequent acute liver failure with a hospital mortality of 88.9%. Duration of heart failure, cause, cardiopulmonary resuscitation, use of vasopressors, central venous pressure, pulmonary capillary wedge pressure, pulmonary pulsatility index, cardiac index, and transaminases were not significantly associated with acute liver failure. Repeated decompensation, atrial fibrillation ( P  &lt; .001) and the use of inotropes ( P  = .007), mean arterial ( P  = .005) and pulmonary pressures ( P  = .042), cholinesterase, international normalized ratio, bilirubin, lactate, and pH ( P  &lt; .001) were predictive of acute liver failure in univariate analysis only. In multivariable analysis, decreased antithrombin III was the strongest single measurement indicating acute liver failure (relative risk per %, 0.84; 95% confidence interval, 0.77-0.93; P  = .001) and remained an independent predictor when adjustment for the Model for End-Stage Liver Disease score was performed (relative risk per %, 0.89; 95% confidence interval, 0.80-0.99; P  = .031). Antithrombin III less than 59.5% was identified as a cutoff value to predict acute liver failure with a corresponding sensitivity of 81% and specificity of 87%. Conclusions In addition to the Model for End-Stage Liver Disease score, decreased antithrombin III activity tends to be superior in predicting acute liver failure compared with traditionally thought predictors. Antithrombin III measurement may help to identify patients more precisely who are developing acute liver failure during mechanical circulatory support.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28274560</pmid><doi>10.1016/j.jtcvs.2017.01.053</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-5223
ispartof The Journal of thoracic and cardiovascular surgery, 2017-06, Vol.153 (6), p.1374-1382
issn 0022-5223
1097-685X
language eng
recordid cdi_proquest_miscellaneous_1876493996
source MEDLINE; Elsevier ScienceDirect Journals Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects acute liver failure
Adult
Aged
Antithrombin III - metabolism
Biomarkers - blood
cardiogenic shock
Cardiothoracic Surgery
extracorporeal membrane oxygenation
Extracorporeal Membrane Oxygenation - adverse effects
Extracorporeal Membrane Oxygenation - mortality
Female
Heart Failure - blood
Heart Failure - mortality
Heart Failure - physiopathology
Heart Failure - therapy
Hemodynamics
Hospital Mortality
Humans
Liver Failure, Acute - blood
Liver Failure, Acute - diagnosis
Liver Failure, Acute - mortality
Liver Failure, Acute - physiopathology
Liver Function Tests
Male
mechanical circulatory support
Middle Aged
Predictive Value of Tests
Retrospective Studies
Risk Factors
Shock, Cardiogenic - blood
Shock, Cardiogenic - mortality
Shock, Cardiogenic - physiopathology
Shock, Cardiogenic - therapy
Time Factors
Treatment Outcome
title Antithrombin III is associated with acute liver failure in patients with end-stage heart failure undergoing mechanical circulatory support
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T16%3A16%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antithrombin%20III%20is%20associated%20with%20acute%20liver%20failure%20in%20patients%20with%20end-stage%20heart%20failure%20undergoing%20mechanical%20circulatory%20support&rft.jtitle=The%20Journal%20of%20thoracic%20and%20cardiovascular%20surgery&rft.au=Hoefer,%20Judith,%20MD&rft.aucorp=Innsbruck%20Liver-in-Heart-Failure%20Program&rft.date=2017-06-01&rft.volume=153&rft.issue=6&rft.spage=1374&rft.epage=1382&rft.pages=1374-1382&rft.issn=0022-5223&rft.eissn=1097-685X&rft_id=info:doi/10.1016/j.jtcvs.2017.01.053&rft_dat=%3Cproquest_cross%3E1876493996%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1876493996&rft_id=info:pmid/28274560&rft_els_id=S0022522317302039&rfr_iscdi=true